SI2303267T1 - Polimorfna oblika derivata (1,2,4)triazolo(4,3-a)piridina za zdravljenje vnetnih bolezni - Google Patents

Polimorfna oblika derivata (1,2,4)triazolo(4,3-a)piridina za zdravljenje vnetnih bolezni

Info

Publication number
SI2303267T1
SI2303267T1 SI200930680T SI200930680T SI2303267T1 SI 2303267 T1 SI2303267 T1 SI 2303267T1 SI 200930680 T SI200930680 T SI 200930680T SI 200930680 T SI200930680 T SI 200930680T SI 2303267 T1 SI2303267 T1 SI 2303267T1
Authority
SI
Slovenia
Prior art keywords
acpyridine
triazolo
derivative
inflammatory diseases
polymorphic form
Prior art date
Application number
SI200930680T
Other languages
English (en)
Inventor
Kenneth John Butcher
Original Assignee
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Limited filed Critical Pfizer Limited
Publication of SI2303267T1 publication Critical patent/SI2303267T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
SI200930680T 2008-02-04 2009-01-28 Polimorfna oblika derivata (1,2,4)triazolo(4,3-a)piridina za zdravljenje vnetnih bolezni SI2303267T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2587908P 2008-02-04 2008-02-04
PCT/IB2009/050351 WO2009098612A2 (en) 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases
EP09708402.4A EP2303267B1 (en) 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-a]pyridine derivative for treating inflammatory diseases

Publications (1)

Publication Number Publication Date
SI2303267T1 true SI2303267T1 (sl) 2013-09-30

Family

ID=40911989

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200930680T SI2303267T1 (sl) 2008-02-04 2009-01-28 Polimorfna oblika derivata (1,2,4)triazolo(4,3-a)piridina za zdravljenje vnetnih bolezni

Country Status (23)

Country Link
US (1) US8222273B2 (sl)
EP (1) EP2303267B1 (sl)
JP (1) JP5344942B2 (sl)
KR (2) KR20130087048A (sl)
CN (1) CN101939320B (sl)
AR (1) AR070411A1 (sl)
AU (1) AU2009211072B2 (sl)
BR (1) BRPI0907463A2 (sl)
CA (1) CA2712574C (sl)
CY (1) CY1114389T1 (sl)
DK (1) DK2303267T3 (sl)
ES (1) ES2423991T3 (sl)
HK (1) HK1147481A1 (sl)
IL (1) IL206948A (sl)
MX (1) MX2010008535A (sl)
NZ (1) NZ587094A (sl)
PL (1) PL2303267T3 (sl)
PT (1) PT2303267E (sl)
RU (1) RU2448966C1 (sl)
SI (1) SI2303267T1 (sl)
TW (1) TWI391391B (sl)
WO (1) WO2009098612A2 (sl)
ZA (1) ZA201005137B (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
JP5877201B2 (ja) 2010-08-30 2016-03-02 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
US20140336159A1 (en) 2011-10-07 2014-11-13 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
CA2858420A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
CN105693716A (zh) * 2016-03-01 2016-06-22 孙霖 晶型a及制备方法
CN105646484A (zh) * 2016-03-01 2016-06-08 孙霖 晶型b及制备方法
GB201721793D0 (en) 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990182A2 (en) 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
PL348502A1 (en) 1998-11-20 2002-05-20 Mitsubishi Chem Corp Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione
US7847112B2 (en) 2004-07-16 2010-12-07 Health Science Funding, LLC Polymorphs of atovaquone and process of preparation thereof
PL1778686T3 (pl) 2004-08-12 2009-04-30 Pfizer Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds

Also Published As

Publication number Publication date
US8222273B2 (en) 2012-07-17
HK1147481A1 (en) 2011-08-12
ZA201005137B (en) 2011-03-30
AR070411A1 (es) 2010-04-07
JP2009185028A (ja) 2009-08-20
CY1114389T1 (el) 2016-08-31
KR20100108409A (ko) 2010-10-06
IL206948A0 (en) 2010-12-30
WO2009098612A2 (en) 2009-08-13
BRPI0907463A2 (pt) 2019-09-24
EP2303267A2 (en) 2011-04-06
CA2712574A1 (en) 2009-08-13
MX2010008535A (es) 2010-08-30
AU2009211072A1 (en) 2009-08-13
WO2009098612A3 (en) 2009-10-08
CN101939320B (zh) 2013-11-20
CN101939320A (zh) 2011-01-05
KR101422318B1 (ko) 2014-07-22
RU2448966C1 (ru) 2012-04-27
PT2303267E (pt) 2013-08-05
RU2010132639A (ru) 2012-02-10
CA2712574C (en) 2014-01-07
US20110003848A1 (en) 2011-01-06
TWI391391B (zh) 2013-04-01
TW200944524A (en) 2009-11-01
NZ587094A (en) 2011-07-29
ES2423991T3 (es) 2013-09-26
KR20130087048A (ko) 2013-08-05
JP5344942B2 (ja) 2013-11-20
DK2303267T3 (da) 2013-09-02
AU2009211072B2 (en) 2014-01-23
PL2303267T3 (pl) 2013-11-29
EP2303267B1 (en) 2013-07-03
IL206948A (en) 2014-12-31

Similar Documents

Publication Publication Date Title
SI2303267T1 (sl) Polimorfna oblika derivata (1,2,4)triazolo(4,3-a)piridina za zdravljenje vnetnih bolezni
HK1136559A1 (en) Process for the preparation of a benzimidazole derivative
HK1154382A1 (en) Triazole derivatives useful for the treatment of diseases
EP2262508A4 (en) SUBSTITUTED p-CHINONE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATIVE STRESS
EP2252148A4 (en) METHOD FOR THE TREATMENT OF DARM DISEASES
EP2365747A4 (en) METHODS OF TREATING GASTROINTESTINAL DISEASES
HK1206003A1 (zh) 有治療價值的三苯基丁烯衍生物的製備方法
EP2403503A4 (en) METHOD FOR THE TREATMENT OF EYE IGNITIONS
HK1155086A1 (en) 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases
IL186904A0 (en) Novel compounds for treating inflammatory diseases
IL209999A0 (en) Nifurtimox for treating diseases caused by trichomonadida
ZA201000670B (en) Process for producing toluidine compound
HUP0700818A2 (en) Process for the preparation of polyirocyanates of the diphenylmethane series
EP2415766A4 (en) PROCESS FOR THE PRODUCTION OF BENZODIAPINE DERIVATIVE
IL204792A0 (en) Method for producing pyrazolinone derivative
ZA200707592B (en) Novel compounds for treating inflammatory diseases
IL206085A0 (en) Process for producing of pyrazolinone derivative
EP2223912A4 (en) PROCESS FOR THE PREPARATION OF A 6-HALOGENO-3-ARYLPYRIDINE DERIVATIVE
EP1997812A4 (en) PROCESS FOR THE PREPARATION OF A CHINAZOLIN-4-ON DERIVATIVE
EP2216337A4 (en) METHOD FOR PRODUCING A 4-DESOXY-4-FLUOR-D-GLUCOSE DERIVATIVE
EP2238120A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF A TRIPHENYLBORON PYRIDINE COMPOUND
AU2009900940A0 (en) Method for treating inflammatory diseases
IL194261A0 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
IL202098A0 (en) One-pot production process for cinnamide derivative